摘要
目的观察疏血通治疗糖尿病合并冠心病血浆纤溶酶原活化物抑制剂-1(PAI-1)及D-二聚体(DD)变化并观察其心绞痛及心电图ST-T的改善。方法将糖尿病合并冠心病患者120例随机分为治疗组60例(在冠心病常规二级预防的基础上加用疏血通治疗14d),对照组(冠心病常规二级预防)60例,分别观察两组治疗前后血浆PAI-1、DD、血浆凝血酶原时间(PT),活化的部分凝血活酶时间(APTT)、国际标准化比值(INR)的变化;心绞痛症状及心电图ST-T改善情况。结果治疗组治疗后PAI-1下降(P<0.05),PT、APTT、INR延长(P<0.05),15例(25%)患者DD值较治疗前升高,但差异无统计学意义(P>0.05),45例(75%)患者较治疗前降低,差异具有统计学意义(P<0.05)。对照组PAI-1、DD、PT、APTT、INR的变化差异无统计学意义,治疗组心绞痛症状及心电图的ST-T较对照组有明显改善。结论疏血通可安全有效降低2型糖尿病合并冠心病患者血浆PAI-1、DD,延长PT、APTT、INR,并明显改善2型糖尿病合并冠心病患者心绞痛症状及心电图ST-T。
Objective To investigate the effects and mechanisms of Shuxuetong on type 2 diabetic patients with coronary heart disease. Methods The 120 type 2 diabetic patients combined with coronary heart disease were randomly divided into treatment group and control group：the 60 of them were treated with routine western medicine（control group）and the other 60 patients（treatment group）were treated with Shuxuetong on the base of routine medicine for 14d. PAI-1, DD, PT, APTT, INR levels were examined and angina symptoms and ECG ST-T were appraised at the following time：before and after the therapy. Results The levels of PAI-1 decreased signifieantly（P〈0.05）in the treatment group; PT,APTT INR prolonged in the treatment group（P〈0.05） ;and the DD level of 25% patients in the treatment group increased, 75 % of them decreased. PAI-1, DD, PT, APTT, INR in the patients of control group changed nonsense; the angina symptoms and ECG ST-T in the treatment group improved significantly compared with those in the control group. Conclusion Shuxuetong can reduce PAI-1, DD, prolong PT, APTT, INR and improve the angina symptoms and ECG STT in type 2 diabetic patients with coronary heart disease.
出处
《重庆医学》
CAS
CSCD
北大核心
2010年第1期53-55,57,共4页
Chongqing medicine
